LARIMAR THERAPEUTICS, INC. Stock-Based Compensation
LARIMAR THERAPEUTICS, INC. (LRMR) reported Stock-Based Compensation of $4.13 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $2.15M, a 17.56% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $1.98M, a 7.91% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $1.56M, a 35.39% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $1.78M, a 8.79% decline year-over-year.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $7.00M, a 20.37% decline from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $8.80M, a 15.51% increase from fiscal 2023.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $7.62M, a 15.05% increase from fiscal 2022.
- LARIMAR THERAPEUTICS, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $6.62M, a 20.94% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $4.13M 10-Q · filed 2026-08-04 | $5.68M derived: sum of 3 quarters · filed 2026-08-04 | $7.47M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $1.98M 10-Q · filed 2026-05-14 | $3.54M derived: sum of 2 quarters · filed 2026-05-14 | $5.32M derived: sum of 3 quarters · filed 2026-05-14 | $7.15M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $3.34M derived: sum of 2 quarters · filed 2026-03-19 | $5.17M derived: sum of 3 quarters · filed 2026-08-04 | $7.00M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $1.78M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $3.61M derived: sum of 2 quarters · filed 2026-08-04 | $5.45M 10-Q · filed 2025-11-05 | $7.86M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $1.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $3.66M 10-Q · filed 2026-08-04 | $6.07M derived: sum of 3 quarters · filed 2026-08-04 | $8.03M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $1.83M 10-Q · filed 2026-05-14 | $4.24M derived: sum of 2 quarters · filed 2026-05-14 | $6.20M derived: sum of 3 quarters · filed 2026-05-14 | $8.50M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | $2.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $4.37M derived: sum of 2 quarters · filed 2026-03-19 | $6.67M derived: sum of 3 quarters · filed 2026-03-19 | $8.80M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | $1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $4.26M derived: sum of 2 quarters · filed 2025-11-05 | $6.39M 10-Q · filed 2025-11-05 | $8.30M derived: sum of 4 quarters · filed 2025-11-05 | ||||
| 2024-06-30 | $2.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $4.43M 10-Q · filed 2025-08-14 | $6.35M derived: sum of 3 quarters · filed 2025-08-14 | $8.17M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | $2.13M 10-Q · filed 2025-04-30 | $4.05M derived: sum of 2 quarters · filed 2025-04-30 | $5.87M derived: sum of 3 quarters · filed 2025-04-30 | $7.91M derived: sum of 4 quarters · filed 2025-04-30 | ||||
| 2023-12-31 | $1.92M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $3.74M derived: sum of 2 quarters · filed 2025-03-24 | $5.78M derived: sum of 3 quarters · filed 2025-03-24 | $7.62M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | $1.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $3.86M derived: sum of 2 quarters · filed 2024-10-30 | $5.70M 10-Q · filed 2024-10-30 | $7.34M derived: sum of 4 quarters · filed 2024-10-30 | ||||
| 2023-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $3.88M 10-Q · filed 2024-08-08 | $5.52M derived: sum of 3 quarters · filed 2024-08-08 | $7.18M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | $1.83M 10-Q · filed 2024-05-09 | $3.48M derived: sum of 2 quarters · filed 2024-05-09 | $5.14M derived: sum of 3 quarters · filed 2024-05-09 | $6.82M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.31M derived: sum of 2 quarters · filed 2024-03-14 | $4.98M derived: sum of 3 quarters · filed 2024-03-14 | $6.62M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | $1.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $3.34M derived: sum of 2 quarters · filed 2023-11-14 | $4.98M 10-Q · filed 2023-11-14 | $6.46M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.31M 10-Q · filed 2023-08-10 | $4.79M derived: sum of 3 quarters · filed 2023-08-10 | $6.25M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $1.64M 10-Q · filed 2023-05-15 | $3.12M derived: sum of 2 quarters · filed 2023-05-15 | $4.58M derived: sum of 3 quarters · filed 2023-05-15 | $5.93M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | $1.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | $2.94M derived: sum of 2 quarters · filed 2023-03-14 | $4.29M derived: sum of 3 quarters · filed 2023-03-14 | $5.47M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | $1.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $2.81M derived: sum of 2 quarters · filed 2022-11-10 | $3.99M 10-Q · filed 2022-11-10 | $5.00M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | $1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $2.53M 10-Q · filed 2022-08-11 | $3.54M derived: sum of 3 quarters · filed 2022-08-11 | $3.91M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | $1.18M 10-Q · filed 2022-05-12 | $2.19M derived: sum of 2 quarters · filed 2022-05-12 | $2.56M derived: sum of 3 quarters · filed 2022-05-12 | $3.31M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | $1.38M derived: sum of 2 quarters · filed 2022-03-25 | $2.13M derived: sum of 3 quarters · filed 2022-03-25 | $2.16M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | $370.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $1.12M derived: sum of 2 quarters · filed 2021-11-12 | $1.15M 10-Q · filed 2021-11-12 | $1.18M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | $752.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $781.00K 10-Q · filed 2021-08-12 | $810.00K derived: sum of 3 quarters · filed 2021-08-12 | $843.00K derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $29.00K 10-Q · filed 2021-05-10 | $710.00K 10-Q · filed 2020-05-07 | $58.00K derived: sum of 2 quarters · filed 2021-05-10 | $91.00K derived: sum of 3 quarters · filed 2021-05-10 | -$1.92M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | $29.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $62.00K derived: sum of 2 quarters · filed 2021-03-04 | -$1.95M derived: sum of 3 quarters · filed 2021-03-04 | $129.00K 10-K · filed 2021-03-04 | $5.50M 10-K · filed 2020-03-05 | |||
| 2019-09-30 | $33.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$1.98M derived: sum of 2 quarters · filed 2020-11-12 | $100.00K 10-Q · filed 2020-11-12 | $4.55M 10-Q · filed 2019-11-06 | $2.39M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | -$2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | $67.00K 10-Q · filed 2020-08-14 | $3.95M 10-Q · filed 2019-08-08 | $2.36M derived: sum of 3 quarters · filed 2020-08-14 | $4.56M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | $2.08M 10-Q · filed 2020-05-07 | $4.37M derived: sum of 2 quarters · filed 2020-05-07 | $6.57M derived: sum of 3 quarters · filed 2020-05-07 | $9.24M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $4.49M derived: sum of 2 quarters · filed 2020-03-05 | $7.16M derived: sum of 3 quarters · filed 2020-03-05 | $9.63M 10-K · filed 2020-03-05 | ||||
| 2018-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $4.87M derived: sum of 2 quarters · filed 2019-11-06 | $7.34M 10-Q · filed 2019-11-06 | $9.44M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | $2.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $5.14M 10-Q · filed 2019-08-08 | $7.24M derived: sum of 3 quarters · filed 2020-03-05 | $9.34M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-03-31 | $2.47M 10-Q · filed 2019-05-09 | $4.57M derived: sum of 2 quarters · filed 2020-03-05 | $6.66M derived: sum of 3 quarters · filed 2020-03-05 | $8.77M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2017-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $4.20M derived: sum of 2 quarters · filed 2020-03-05 | $6.30M derived: sum of 3 quarters · filed 2020-03-05 | $8.30M 10-K · filed 2020-03-05 | ||||
| 2017-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $4.20M derived: sum of 2 quarters · filed 2018-11-09 | $6.20M 10-Q · filed 2018-11-09 | $8.21M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $4.10M 10-Q · filed 2018-08-09 | $6.11M derived: sum of 3 quarters · filed 2019-03-14 | $8.61M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2017-03-31 | $2.00M 10-Q · filed 2018-05-10 | $4.01M derived: sum of 2 quarters · filed 2019-03-14 | $6.50M derived: sum of 3 quarters · filed 2019-03-14 | $9.36M derived: sum of 4 quarters · filed 2019-03-14 | ||||
| 2016-12-31 | $2.01M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-14 | $4.50M derived: sum of 2 quarters · filed 2019-03-14 | $7.36M derived: sum of 3 quarters · filed 2019-03-14 | $10.11M 10-K · filed 2019-03-14 | ||||
| 2016-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $5.35M derived: sum of 2 quarters · filed 2017-11-07 | $8.11M 10-Q · filed 2017-11-07 | $10.85M derived: sum of 4 quarters · filed 2018-03-09 | ||||
| 2016-06-30 | $2.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $5.61M 10-Q · filed 2017-08-09 | $8.36M derived: sum of 3 quarters · filed 2018-03-09 | |||||
| 2016-03-31 | $2.76M 10-Q · filed 2017-05-09 | $5.50M derived: sum of 2 quarters · filed 2018-03-09 | ||||||
| 2015-12-31 | $2.75M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | $8.58M 10-K · filed 2018-03-09 | ||||||
| 2015-09-30 | $5.84M 10-Q · filed 2016-11-09 | |||||||
| 2014-12-31 | $1.55M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |